XTalks

JULY 14, 2021

In this episode, Ayesha talks about Nestlé’s marketing of Seres Therapeutics’ oral microbiome drug for recurrent C. CDIs typically develop after the use of antibiotics, which can wipe out the gut’s healthy bacteria. Nestlé to Market Seres’ Oral Microbiome Drug for C. Difficile infection (CDI). Read the full articles here: .

Bacteria 52

Bacteria Marketing Drugs Containment 52

XTalks

NOVEMBER 28, 2023

Indicated for the treatment of trichomoniasis in adults, amebiasis in both adults and pediatric patients and anaerobic bacterial infections in adults, Likmez is available as an oral suspension, with each 5 mL containing 500 mg of metronidazole.

FDA Approval 103

FDA Approval Bacteria DNA Drugs 103

Drug Discovery World

AUGUST 9, 2022

Provider to the life sciences industry BioIVT has acquired enzymes manufacturer Cypex in a bid to enhance its product portfolio. . This technology enables the expression of human drug-metabolizing enzymes in bacteria, without requiring large modifications to the proteins.? . Richard Haigh.

In-Vitro 52

In-Vitro Protein Production Bacteria 52

XTalks

DECEMBER 2, 2022

difficile as certain antibiotics can disrupt the balance of bacteria in the gut, allowing bacteria like C. Related: Nestlé to Market Seres’ Oral Microbiome Drug for C. Additionally, Rebyota could contain food allergens, which poses an unknown risk for food allergen-related adverse reactions. Difficile. “As

FDA Approval 59

FDA Approval Bacteria Containment Clinical Trials 59

Drug Discovery World

APRIL 11, 2024

Successful projects will gain access to UKHSA facilities where they can test clinical strains of bacteria and get support from experts in the field. The UK’s national action plan for AMR aims to see the problem effectively contained and controlled by 2040. He has a master’s degree in Journalism from Newcastle University.

Bacteria 52

Bacteria Life Science Development Containment 52

Drug Discovery World

SEPTEMBER 28, 2023

This is likely in part because their byproduct, lactic acid, is known to inhibit pathogenic bacteria 25. And, in the endometrium, a decrease in Lactobacillus may affect embryo attachment and promote the growth of detrimental bacteria. The influence of these microbiomes extends to children as well.

Clinical Trials 64

Clinical Trials Clinical Trials Regulation Bacteria 64

XTalks

MAY 17, 2024

Given concerns about safety, the company said no unsafe products should be on the market, especially given that neither the FDA nor any global regulatory agency has reviewed the compounded products for safety, quality or efficacy.

Sales 52

Sales FDA Approval Pharmacy Production 52